206 related articles for article (PubMed ID: 21638329)
1. Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies.
O'Gorman C; Kapur S; Kolluri S; Kane J
Hum Psychopharmacol; 2011; 26(4-5):282-90. PubMed ID: 21638329
[TBL] [Abstract][Full Text] [Related]
2. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
5. Early prediction of clinical and functional outcome in schizophrenia.
Agid O; Siu CO; Pappadopulos E; Vanderburg D; Remington G
Eur Neuropsychopharmacol; 2013 Aug; 23(8):842-51. PubMed ID: 23141372
[TBL] [Abstract][Full Text] [Related]
6. Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: analyses of ziprasidone clinical study data.
Masand P; O'Gorman C; Mandel FS
Schizophr Res; 2011 Mar; 126(1-3):174-83. PubMed ID: 21185155
[TBL] [Abstract][Full Text] [Related]
7. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia.
Simpson GM; Weiden P; Pigott T; Murray S; Siu CO; Romano SJ
Am J Psychiatry; 2005 Aug; 162(8):1535-8. PubMed ID: 16055779
[TBL] [Abstract][Full Text] [Related]
8. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.
Grootens KP; van Veelen NM; Peuskens J; Sabbe BG; Thys E; Buitelaar JK; Verkes RJ; Kahn RS
Schizophr Bull; 2011 Mar; 37(2):352-61. PubMed ID: 19542525
[TBL] [Abstract][Full Text] [Related]
9. A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study.
Addington DE; Labelle A; Kulkarni J; Johnson G; Loebel A; Mandel FS
Can J Psychiatry; 2009 Jan; 54(1):46-54. PubMed ID: 19175979
[TBL] [Abstract][Full Text] [Related]
10. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Olié JP; Spina E; Murray S; Yang R
Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
[TBL] [Abstract][Full Text] [Related]
11. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
Breier A; Berg PH; Thakore JH; Naber D; Gattaz WF; Cavazzoni P; Walker DJ; Roychowdhury SM; Kane JM
Am J Psychiatry; 2005 Oct; 162(10):1879-87. PubMed ID: 16199834
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and tolerability of oral ziprasidone in psychiatric inpatients with an acute exacerbation of schizophrenia or schizoaffective disorder: a multicenter, prospective, and naturalistic study.
Díaz-Marsá M; Sánchez S; Rico-Villademoros F;
J Clin Psychiatry; 2009 Apr; 70(4):509-17. PubMed ID: 19358789
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
Weiden PJ; Simpson GM; Potkin SG; O'Sullivan RL
J Clin Psychiatry; 2003 May; 64(5):580-8. PubMed ID: 12755663
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
[TBL] [Abstract][Full Text] [Related]
15. Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia.
Simpson GM; O'Gorman CJ; Loebel A; Yang R
CNS Spectr; 2008 Oct; 13(10):898-905. PubMed ID: 18955945
[TBL] [Abstract][Full Text] [Related]
16. Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies.
Lawson WB; Herman BK; Loebel A; Lazariciu I; Malik M
CNS Spectr; 2009 Sep; 14(9):478-86. PubMed ID: 19890230
[TBL] [Abstract][Full Text] [Related]
17. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder.
Potkin SG; Ogasa M; Cucchiaro J; Loebel A
Schizophr Res; 2011 Nov; 132(2-3):101-7. PubMed ID: 21889878
[TBL] [Abstract][Full Text] [Related]
18. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.
Keck PE; Versiani M; Potkin S; West SA; Giller E; Ice K;
Am J Psychiatry; 2003 Apr; 160(4):741-8. PubMed ID: 12668364
[TBL] [Abstract][Full Text] [Related]
19. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.
Meltzer HY; Cucchiaro J; Silva R; Ogasa M; Phillips D; Xu J; Kalali AH; Schweizer E; Pikalov A; Loebel A
Am J Psychiatry; 2011 Sep; 168(9):957-67. PubMed ID: 21676992
[TBL] [Abstract][Full Text] [Related]
20. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.
Zimbroff D; Warrington L; Loebel A; Yang R; Siu C
Int Clin Psychopharmacol; 2007 Nov; 22(6):363-70. PubMed ID: 17917555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
